雅本化學(300261.SZ):目前公司的大健康業務尚處於培育階段
格隆匯7月20日丨雅本化學(300261.SZ)近期在接待機構投資者調研時表示,公司基於生物酶領域長期的技術沉澱及商業化生產經驗,開拓大健康業務。公司大健康業務有兩個發展思路,一是關注上游原料的生產和銷售市場,力爭以技術進步實現成本控制和質量提升,從而將公司打造成有市場競爭力的原料供應商;二是持續關注消費端市場機會,推出有市場競爭力的C端產品。但目前公司的大健康業務尚處於培育階段,對公司業績貢獻較低,外部市場環境不確定性較大。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.